中国医药导刊
中國醫藥導刊
중국의약도간
CHINESE JOURNAL OF MEDICAL GUIDE
2014年
4期
639-640
,共2页
原发纵膈性%淋巴瘤%化学疗法%放射疗法
原髮縱膈性%淋巴瘤%化學療法%放射療法
원발종격성%림파류%화학요법%방사요법
PMBL%Lymphoma%Chemotherapy%Radiotherapy
目的：观察原发纵膈性B细胞型淋巴瘤的最佳治疗方案。方法：R-CHOP组予6疗程R-CHOP(美罗华+环磷酰胺+阿霉素+长春新碱+泼尼松)方案后评估疗效选择是否放疗,DA-EPOCH-R组予6疗程DA-EPOCH-R(美罗华+依托泊甙+多柔比星+长春新碱+环磷酰胺+强的松)方案后评估疗效选择是否放疗。结果：R-CHOP组患者73%接受放疗,48个月的EFS为78%,DA-EPOCH-R组7.7%接受放疗,48个月的EFS为95%(P值均<0.05)。结论：DA-EPOCH-R方案对多数PMBL患者来说排除了放疗的需要,继而减少了放疗的长期毒性。
目的：觀察原髮縱膈性B細胞型淋巴瘤的最佳治療方案。方法：R-CHOP組予6療程R-CHOP(美囉華+環燐酰胺+阿黴素+長春新堿+潑尼鬆)方案後評估療效選擇是否放療,DA-EPOCH-R組予6療程DA-EPOCH-R(美囉華+依託泊甙+多柔比星+長春新堿+環燐酰胺+彊的鬆)方案後評估療效選擇是否放療。結果：R-CHOP組患者73%接受放療,48箇月的EFS為78%,DA-EPOCH-R組7.7%接受放療,48箇月的EFS為95%(P值均<0.05)。結論：DA-EPOCH-R方案對多數PMBL患者來說排除瞭放療的需要,繼而減少瞭放療的長期毒性。
목적：관찰원발종격성B세포형림파류적최가치료방안。방법：R-CHOP조여6료정R-CHOP(미라화+배린선알+아매소+장춘신감+발니송)방안후평고료효선택시부방료,DA-EPOCH-R조여6료정DA-EPOCH-R(미라화+의탁박대+다유비성+장춘신감+배린선알+강적송)방안후평고료효선택시부방료。결과：R-CHOP조환자73%접수방료,48개월적EFS위78%,DA-EPOCH-R조7.7%접수방료,48개월적EFS위95%(P치균<0.05)。결론：DA-EPOCH-R방안대다수PMBL환자래설배제료방료적수요,계이감소료방료적장기독성。
Objective: Objective to discuss whether DA-EPOCH-R was excelled than R-CHOP. It was possible that DA-EPOCH-R reduced the side reactions and adverse reactions of radiotherapy. Methods:12 PMBL patients accepted 6R-CHOP,14 PMBL patients accepted 6DA-EPOCH-R. Their adverse reactions and the related reactions of chemotherapy were observed. Results:Outcome of 78%EFS and 96%OS at 4 years in Routcome of 78%EFS and 96%OS at 4 years in R-CHOP, and 95%EFS and 100%OS at 4 years in DA-EPOCH-R(P<0.05). Conclution:After the evaluation, 6 patients who had accepted R-CHOP accepted radiotherapy, and 1 patient who had accepted DA-EPOCH-R accepted radiotherapy.
